United Laboratories Unit Gets $180 Million Upfront Payment from Novo Nordisk

Published on 06/20/2025 at 03:09

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about The United Laboratories International Holdings Limited

UOB Kay Hian Upgrades The United Laboratories International Holdings to Buy from Hold; Price Target is HK$19	Jul. 16	MT
The United Laboratories International Holdings Limited Announces FDA Approval of IND for UBT37034 Injection	Jul. 10	CI
United Laboratories International flaunts U.S. FDA approval of IND for UBT37034 injection	Jul. 10	RE
United Laboratories Unit Gets US FDA Nod for IND Application of Obesity Injection	Jul. 10	MT
United Laboratories International Says United Biotechnology Got Upfront Payment From Novo Nordisk	Jun. 20	RE
United Laboratories Unit Gets $180 Million Upfront Payment from Novo Nordisk	Jun. 20	MT
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple	Jun. 11	RE
TF Securities Starts The United Laboratories International Holdings at Buy with HK$18.77 Price Target	May. 20	MT
United Laboratories Unit's Infection Drug Passes Chinese Regulator's Consistency Evaluation	Apr. 15	MT
United Laboratories International Says Group's Product Cefotaxime Sodium For Injection Passed Consistency Evaluation	Apr. 15	RE
United Laboratories to Repurchase HK$200 Million of Shares; Shares Plunge 18%	Apr. 07	MT
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal	Mar. 28	RE
Zhongtai International Downgrades The United Laboratories International to Neutral from Buy; Price Target is HK$14.50	Mar. 28	MT
Jefferies Adjusts The United Laboratories International's Price Target to HK$17 from HK$15, Keeps at Buy	Mar. 26	MT
United Laboratories, Novo Nordisk Sign $1.8 Billion License Deal for Global Rights to Diabetes and Obesity Drug	Mar. 26	MT
United Laboratories International Says Final Dividend Of RMB28 Cents Per Share	Mar. 25	RE
Merck buys rights to heart disease drug in latest China deal	Mar. 25	RE
Health Care Up, But not by Much, on Cyclical Bias -- Health Care Roundup	Mar. 24	DJ
Deals of the day-Mergers and acquisitions	Mar. 24	RE
United Laboratories International Declares Special Dividend	Mar. 24	RE
The United Laboratories International Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 24	CI
Novo Nordisk Strikes Up to $2 Billion Licensing Deal for Chinese Firm's Obesity, Diabetes Drug Candidate	Mar. 24	MT
United Laboratories International Announces Exclusive License Agreement With Novo Nordisk	Mar. 24	RE
Novo Nordisk Signs $2 Billion Deal for Experimental Obesity Drug -- Update	Mar. 24	DJ
United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist	Mar. 24	RE